- Home
- TPCS vs RNXT Comparison
TPCS vs RNXT Comparison
Compare TPCS & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPCS
- RNXT
- Stock Information
- Founded
- TPCS 1956
- RNXT 2012
- Country
- TPCS United States
- RNXT United States
- Employees
- TPCS N/A
- RNXT N/A
- Industry
- TPCS Metal Fabrications
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- TPCS Industrials
- RNXT Health Care
- Exchange
- TPCS Nasdaq
- RNXT Nasdaq
- Market Cap
- TPCS 27.2M
- RNXT 34.0M
- IPO Year
- TPCS N/A
- RNXT 2021
- Fundamental
- Price
- TPCS $2.60
- RNXT $0.94
- Analyst Decision
- TPCS
- RNXT Strong Buy
- Analyst Count
- TPCS 0
- RNXT 1
- Target Price
- TPCS N/A
- RNXT $9.00
- AVG Volume (30 Days)
- TPCS 48.3K
- RNXT 139.2K
- Earning Date
- TPCS 01-21-2025
- RNXT 05-09-2025
- Dividend Yield
- TPCS N/A
- RNXT N/A
- EPS Growth
- TPCS N/A
- RNXT N/A
- EPS
- TPCS N/A
- RNXT N/A
- Revenue
- TPCS $33,182,059.00
- RNXT N/A
- Revenue This Year
- TPCS N/A
- RNXT N/A
- Revenue Next Year
- TPCS N/A
- RNXT N/A
- P/E Ratio
- TPCS N/A
- RNXT N/A
- Revenue Growth
- TPCS 6.44
- RNXT N/A
- 52 Week Low
- TPCS $2.16
- RNXT $0.77
- 52 Week High
- TPCS $5.95
- RNXT $1.82
- Technical
- Relative Strength Index (RSI)
- TPCS 36.02
- RNXT 35.61
- Support Level
- TPCS $2.68
- RNXT $0.91
- Resistance Level
- TPCS $3.00
- RNXT $1.03
- Average True Range (ATR)
- TPCS 0.25
- RNXT 0.07
- MACD
- TPCS -0.00
- RNXT 0.00
- Stochastic Oscillator
- TPCS 48.89
- RNXT 23.50
About TPCS TechPrecision Corporation Common stock
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.